BNGO News & Events

Bionano Genomics announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping, OGM, detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia cases - nearly double the 55% detection rate achieved by conventional cytogenetic analysis. Conducted by researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine and representing one of the most comprehensive genomic analyses of T-ALL to date, the study underscores OGM's potential to transform how this aggressive blood cancer is studied and understood.

Bionano Genomics files $400M mixed securities shelf

Bionano Genomics announced that Al Luderer, chairman of Bionano's board of directors, has been appointed interim president and chief executive officer, effective May 5. Luderer will continue to serve as chairman, and director Chris Twomey will serve as lead independent director. He succeeds Erik Holmlin who is staying on as an advisor.